- Canada Research Chair in Immune Regulation (Tier 1, 2001-17)
- Director, Advanced Degrees in Medicine
- Co-Director, National Training Program in Inflammation and Allergy
- Professor, Departments of Immunology; Medical Microbiology; Pediatrics and Child Health
Post Doctoral Fellowship, Harvard Medical School (1983-1986)
Ph.D. (Immunology), University of Western Ontario (1983)
B.Sc. (Hons), Queen's University, Kingston (1978)
Department of Immunology
Max Rady College of Medicine
Rady Faculty of Health Sciences
University of Manitoba
427 Apotex Centre
750 McDermot Avenue
Office Phone: (204) 789-3793
Fax: (204) 789-3921
Lab: (204) 789-3740
Current Research Interests:
The majority of our research is conducted in human systems, ranging from small populations to large national cohorts. Located within the newly opened Apotex Centre on the Bannatyne campus, our modern labs provide extensive, modern research infrastructure. Funding is from CIHR, CFI, CRC, MICH and other agencies. Laboratory members include MSc, PhD and Postdoctoral Fellow research trainees, professional staff (Research Associate, Technicians) and Co-op students.
Our goal is to better understand immune regulation and how it determines whether health or chronic disease dominates. To do this, we focus on how the human immune response is turned on, how it commits to particular types of immunity (good or bad) and how it is turned off. Our goal is to translate this knowledge to improve human health. Most of our research is on the role of cytokine and chemokine responses that result from innate or antigen-specific T cell activation.
We work on normal development of immunity in babies, teens and adults, and on what factors influence development of allergic diseases such as food allergy and allergic asthma. Individual projects in our lab include determining the roles that immune responses to respiratory viruses play, discovering differential pattern recognition receptor function (TLR, NLR, RLR) in different clinical phenotypes, and identifying the roles that vitamin D status plays in health vs disease. Our current studies range from small groups of specially selected volunteers with peanut allergy to large provincial or national cohorts involving up to 5000 babies.
We also participate in a variety of translational collaborative studies including :
- biomarker discovery / validation (in allergic diseases and in solid organ transplantation),
- SyMBIOTA, an investigation of the role of the microbiome in early life in shaping future immune /clinical status in humans (CIHR),
- assessing the therapeutic potential of PI3K subunit selective inhibitors for immune modulation of acute or chronic inflammation, and
- evaluating the impact of organic pollutants (ie. PFOS) on development of immune capacity (PFOS) in neonates.
We are also site leaders for the Canadian Human Immunology network (CIHR), created in 2011, to encourage more research focus on human immunology.
HayGlass publications on PubMed